Clayton Fletcher - BioCryst Pharmaceuticals Chief Officer

BCRX Stock  USD 7.63  0.01  0.13%   

Executive

Clayton Fletcher is Chief Officer of BioCryst Pharmaceuticals
Phone919 859 1302
Webhttps://www.biocryst.com

BioCryst Pharmaceuticals Management Efficiency

BioCryst Pharmaceuticals' management efficiency ratios could be used to measure how well BioCryst Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
BioCryst Pharmaceuticals currently holds 12.82 M in liabilities with Debt to Equity (D/E) ratio of 2.4, implying the company greatly relies on financing operations through barrowing. BioCryst Pharmaceuticals has a current ratio of 5.09, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about BioCryst Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Michael PharmDCassava Sciences
N/A
Richard BarryCassava Sciences
66
Werner GladdinesImmunic
N/A
Chris McChalicherSeres Therapeutics
N/A
Inderpal SinghImmunic
58
Adebayo LaniyonuAnavex Life Sciences
N/A
John DoyleCognition Therapeutics
48
Terrie KellmeyerAnavex Life Sciences
N/A
PharmD MBAMadrigal Pharmaceuticals
N/A
Debra DursoBumpusBlueprint Medicines Corp
55
Adam TownsendApellis Pharmaceuticals
47
MBA MDX4 Pharmaceuticals
62
Ariel HurleyBlueprint Medicines Corp
51
Edward ChiangMadrigal Pharmaceuticals
N/A
Kun JinAnavex Life Sciences
N/A
Pharm MPHX4 Pharmaceuticals
N/A
Ari MaizelAxsome Therapeutics
N/A
MS MBAPDS Biotechnology Corp
59
PharmD MordwinkinKezar Life Sciences
43
Rajani MDAtara Biotherapeutics
N/A
Pr MDApellis Pharmaceuticals
N/A
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. Biocryst Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 358 people. BioCryst Pharmaceuticals (BCRX) is traded on NASDAQ Exchange in USA. It is located in 4505 Emperor Boulevard, Durham, NC, United States, 27703 and employs 580 people. BioCryst Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification.

Management Performance

BioCryst Pharmaceuticals Leadership Team

Elected by the shareholders, the BioCryst Pharmaceuticals' board of directors comprises two types of representatives: BioCryst Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioCryst. The board's role is to monitor BioCryst Pharmaceuticals' management team and ensure that shareholders' interests are well served. BioCryst Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioCryst Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Alane Barnes, VP, General Counsel and Corporate Secretary
Yarlagadda Babu, Sr. VP of Drug Discovery
Elliott Berger, VP Affairs
William MBBS, Chief Officer
Stephanie Angelini, Chief Officer
Michael Jones, Executive Officer
Clayton Fletcher, Chief Officer
Jon Stonehouse, CEO and President and Executive Director
Philip George, Chief Officer
Salisa Hauptmann, Chief Officer
John Bluth, IR Contact Officer
Charles Gayer, Senior Officer
Jinky Rosselli, Chief Officer
Anthony Doyle, Senior CFO
MD FAAP, Chief Officer

BioCryst Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BioCryst Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BioCryst Stock Analysis

When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.